Timm Medical Broadens Incontinence Portfolio With UroSurge Acquisition
This article was originally published in The Gray Sheet
Executive SummaryTimm Medical Technologies plans to proceed with clinical trials of UroSurge's implantable SANS stoller afferent nerve stimulation device for treatment of urinary incontinence if its acquisition of UroSurge closes May 31 as planned. Financial terms of the deal were not disclosed.
You may also be interested in...
New medicines under evaluation at the European Medicines Agency.